ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2017
Market approval for drugs in the EU: time to change direction?
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Best practices in the African Medicines Regulatory Harmonization initiative: Perspectives of regulators and medicines manufacturers.PLOS global public health · 2023Article
- Pharmaceutical pricing in Europe: time to take the right direction.Internal and emergency medicine · 2022Article
- HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?Journal of the Royal Society of Medicine · 2020Article
- Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.PharmacoEconomics · 2020Article
- How do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation.Ecancermedicalscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28028622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.